In recent market activity, Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), has sold a significant amount of company stock, according to a new SEC filing. The transactions, which took place on May 29, 2024, involved the sale of 12,000 shares of common stock at an average price of $21.564, and an additional 2,123 shares at an average price of $22.5212, totaling approximately $260,800.
The sales were executed in multiple trades within the price ranges of $21.2024 to $22.19 for the first batch of shares and $22.2051 to $22.7331 for the second. These transactions were carried out under a pre-arranged trading plan, known as a Rule 10b5-1 trading plan, which Lyssikatos had adopted on June 26, 2023.
In addition to the sales, Lyssikatos also acquired 12,000 shares of Enliven Therapeutics stock through the exercise of options at a striking price of $1.12 per share, amounting to a total of $13,440. It should be noted that all the shares subject to this option were fully vested and exercisable at the time of the transaction.
Following these transactions, Lyssikatos no longer holds any direct shares of Enliven Therapeutics' common stock, as indicated in the filing. However, he does have an indirect stake through The Lyssikatos Revocable Trust, for which he serves as trustee, which holds 1,117,035 shares.
The transactions were disclosed in a Form 4 filing with the Securities and Exchange Commission, which provides a transparent record of insider trading activities. Investors and analysts often monitor such filings for insights into executives' perspectives on their company's prospects.
Enliven Therapeutics, Inc., headquartered in Boulder, Colorado, operates in the pharmaceutical preparations industry and is known for its focus on innovative therapies. The company's stock is publicly traded under the ticker symbol ELVN on the NASDAQ exchange.
InvestingPro Insights
Enliven Therapeutics, Inc. (NASDAQ:ELVN) has been in the spotlight following insider trading activity by its Chief Scientific Officer. To provide a deeper understanding of the company's financial health and performance, we turn to InvestingPro data and tips. With a market capitalization of $1.06 billion, ELVN has demonstrated significant price volatility, as evidenced by a substantial six-month total return of 100.18%. This volatility is further reflected in the company's price, which is currently at 86.06% of its 52-week high.
Despite the impressive short-term returns, Enliven Therapeutics faces financial challenges. The company's P/E ratio stands at -11.46, and it has an adjusted P/E ratio of -13.42 for the last twelve months as of Q1 2024. The negative earnings per share of -$1.92 indicate that ELVN has not been profitable over the past year. In terms of liquidity, ELVN's balance sheet shows strength with more cash than debt and liquid assets that exceed short-term obligations. However, the company does not pay a dividend, which may be a consideration for income-focused investors.
InvestingPro Tips highlight that while ELVN has experienced a large price uptick over the last six months, it suffers from weak gross profit margins. For investors seeking a comprehensive analysis, there are additional tips available on InvestingPro, including insights into the company's financials and forecasts. To explore these further and gain a more nuanced view of ELVN's investment potential, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at https://www.investing.com/pro/ELVN.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.